These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10923560)

  • 1. What is the long-term efficacy and tolerability of orlistat, a gastrointestinal lipase inhibitor, for the treatment of obesity in primary care?
    Leiser JP; Gunning K
    J Fam Pract; 2000 Jun; 49(6):572-3. PubMed ID: 10923560
    [No Abstract]   [Full Text] [Related]  

  • 2. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orlistat for obesity.
    Med Lett Drugs Ther; 1999 Jun; 41(1055):55-6. PubMed ID: 10436767
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
    Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
    Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orlistat half the dose without a prescription: new status. In excess body weight: often uncomfortable and don't expect miracles. Frequent gastrointestinal disturbances for a weight loss of a few kilos. Better to encourage dietary measures, exercise and individualised support.
    Prescrire Int; 2009 Jun; 18(101):101. PubMed ID: 19637413
    [No Abstract]   [Full Text] [Related]  

  • 6. Orlistat: new preparation. No hurry . .
    Prescrire Int; 1999 Aug; 8(42):99-104. PubMed ID: 11503834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orlistat. No hurry...
    Can Fam Physician; 1999 Oct; 45():2331-3, 2336-8, 2343-5 passim. PubMed ID: 10540693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National trends in the use and costs of anti-obesity medications in England 1998-2005.
    Srishanmuganathan J; Patel H; Car J; Majeed A
    J Public Health (Oxf); 2007 Jun; 29(2):199-202. PubMed ID: 17494061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Orlistat and articles accepted for publication in Medicina Clínica].
    Zambrana García JL; Cruz Caparrós G; Salas Coronas J; Díez García F
    Med Clin (Barc); 1999 Nov; 113(18):716. PubMed ID: 10650576
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orlistat.
    Wong NN; Cheng-Lai A
    Heart Dis; 2000; 2(2):174-81. PubMed ID: 11728255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orlistat for the treatment of obesity: cost utility model.
    Foxcroft DR
    Obes Rev; 2005 Nov; 6(4):323-8. PubMed ID: 16246217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
    Madsen EL; Bruun JM; Skogstrand K; Hougaard DM; Christiansen T; Richelsen B
    Metabolism; 2009 Jul; 58(7):946-53. PubMed ID: 19409578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
    Hill JO; Hauptman J; Anderson JW; Fujioka K; O'Neil PM; Smith DK; Zavoral JH; Aronne LJ
    Am J Clin Nutr; 1999 Jun; 69(6):1108-16. PubMed ID: 10357727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity: can a new drug help?
    Harv Mens Health Watch; 1999 Oct; 4(3):6-8. PubMed ID: 10529295
    [No Abstract]   [Full Text] [Related]  

  • 17. Orlistat: a second look. At best, a minor adjunct to dietary measures.
    Prescrire Int; 2002 Feb; 11(57):10-2. PubMed ID: 11985367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
    Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
    Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
    Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fat-normalizing nutrition. Therewith your patients escape from the yo-yo effect].
    MMW Fortschr Med; 2003 Mar; 145(13):58. PubMed ID: 15101543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.